NCT07064525View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

December 15, 2025

Study Completion Date

February 28, 2026

Conditions
Hypertension (HTN)NYHA Class III Heart FailureNYHA Class IV Heart FailureDiabete Mellitus
Interventions
DRUG

SPC1001 Low

low-dose combination therapy

DRUG

SPC5002

low-dose combination therapy

DRUG

SPC5003

low-dose combination therapy

DRUG

SPC5004

low-dose combination therapy

Trial Locations (1)

06135

CHA Gangnam Medical Center, CHA University, Seoul

All Listed Sponsors
lead

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY